雷贝拉唑治疗十二指肠溃疡的临床观察

目的验证与评估雷贝拉唑治疗十二指肠溃疡的临床疗效和安全性。方法将活动期十二指肠溃疡患者随机分为雷贝拉唑(10 mg/d)治疗组和奥美拉唑(20 mg/d)对照组。服药4周后,胃镜观察溃疡愈合程度并观察有无不良反应出现。结果4周后治疗组和对照组溃疡愈合率分别为95.0%和93.6%,总有效率分别为99.0%和98.9%,两组无显著性差异(P>0.05),但治疗组腹痛消失更为迅速,治疗组第1天腹痛消失率为33.0%,而对照组为18.8%,有显著性差异(P<0.05)。结论雷贝拉唑和奥美拉唑治疗十二指肠溃疡均具有良好疗效,而雷贝拉唑第1天对腹痛的缓解作用更为明显,且无严重不良反应,值得临床上推广。

A Clinical Trial of Rabeprazole in the Treatment of Duodenal Ulcer

Objective To evaluate the effect and safety of Rabeprazole on patients with duodenal ulcer.Methods Patients with duodenal ulcer in active phase were randomly divided into group A(rabeprazole 10 mg/d) and group B(omeprozole 20 mg/d).After 4 weeks treatment,the curative effect was detected by gastroscope and the side-effect was observed.Results After weeks of treatment,the healing rate of ulcer and total effective ratio in group A were 95.0% and 99.0%,and in group B,they were 93.6% and 98.9%.There were no significance between group A and B(P>0.05).But the disappear rate of bellyache in group A was higher than that in group B(P<0.05).After 1 day treatment,in group A,33.0% patients' bellyache disappeared,but in group B,it's 18.8%.Conclusions The effects of rabeprazole and Omeprazole for duodenal ulcer is satisfactory.Rabeprazole is more effective cure for remitting abdominal pain and have little side-effect.